Back to Journals » Drug Design, Development and Therapy » Volume 12

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors

Authors Yang H, Shen K, Zhu C, Li Q, Zhao Y, Ma X

Received 11 January 2018

Accepted for publication 27 March 2018

Published 6 July 2018 Volume 2018:12 Pages 2085—2096

DOI https://doi.org/10.2147/DDDT.S162214

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Qiongyu Guo


Hui Yang,1,2,* Kai Shen,3,* Chenjing Zhu,3 Qingfang Li,3 Yunuo Zhao,2 Xuelei Ma3,*

1Cancer Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2West China School of Medicine, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 3State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, People’s Republic of China

*These authors contributed equally to this work

Introduction: The prominent immune checkpoint molecule, programmed cell death ligand-1 (PD-L1), is the object of increasing attention. Here, we report a meta-analysis investigating the safety and efficacy of durvalumab (MEDI4736), an inhibitor of PD-L1, in various solid tumors.
Methods: A systematic search of PubMed, Embase, and related articles was performed. Safety data were analyzed using Comprehensive Meta-Analysis software program version 2. Ultimately, 17 studies with 1,529 patients were included in our analysis.
Results: The major adverse events associated with durvalumab were pruritus and fatigue, while pruritus, increased alanine transaminase, and increased aspartate aminotransferase were common among patients treated with a combination of durvalumab and tremelimumab. Higher PD-L1 expression was associated with a superior objective response rate.
Conclusion: Durvalumab is safe in patients with many solid cancers and, in combination with tremelimumab, it has a tolerable safety profile and is associated with improved prognosis. PD-L1 expression is a biomarker of the efficacy of durvalumab.

Keywords: durvalumab, solid cancers, adverse effects, efficacy, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]